SCHEMBL3011399

SCHEMBL3011399

COc1ccc(OC)c(-c2csc(N3CCN(S(=O)(=O)c4cccc(Cl)c4Cl)CC3)n2)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
REV1 Q9UBZ9 1/20 0.54
MAPT P10636 9/20 0.52
HSD17B10 Q99714 3/20 0.52
RECQL P46063 2/20 0.52
USP2 O75604 2/20 0.52
ALDH1A1 P00352 9/20 0.47
KMT2A Q03164 7/20 0.47
LMNA P02545 6/20 0.46
MAPK1 P28482 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 5/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPC1 O15118 1/20 0.44
HTT P42858 4/20 0.44
HPGD P15428 1/20 0.43
GAA P10253 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2998079 0.93 MAPT (0.52) REV1MAPTHSD17B10RECQLUSP2
SCHEMBL3006754 0.93 REV1 (0.56) REV1MAPTHSD17B10RECQLUSP2
SCHEMBL3012617 0.89 LMNA (0.52) REV1MAPTHSD17B10RECQLUSP2
SCHEMBL3022575 0.88 KMT2A (0.58) REV1MAPTHSD17B10RECQLUSP2
SCHEMBL3016303 0.87 REV1 (0.54) REV1MAPTHSD17B10RECQLUSP2
SCHEMBL2999117 0.87 REV1 (0.50) REV1MAPTHSD17B10RECQLUSP2
SCHEMBL3010407 0.87 REV1 (0.57) REV1MAPTHSD17B10RECQLUSP2
SCHEMBL3016814 0.86 REV1 (0.53) REV1MAPTHSD17B10RECQLUSP2
SCHEMBL3016180 0.86 REV1 (0.53) REV1MAPTHSD17B10RECQLUSP2
SCHEMBL3008929 0.86 REV1 (0.55) REV1MAPTHSD17B10RECQLUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA REV1 4692/4885MAPT 18/4885HSD17B10 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.